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Abstract
Cytochrome P450s and other heme-containing proteins have recently been shown to have 
promiscuous activity for the cyclopropanation of olefins using diazoacetate reagents. Despite the 
progress made thus far, engineering selective catalysts for all possible stereoisomers for the 
cyclopropanation reaction remains a considerable challenge. Previous investigations of a model 
P450 (P450BM3) revealed that mutation of a conserved active site threonine (Thr268) to alanine 
transformed the enzyme into a highly active and selective cyclopropanation catalyst. By 
incorporating this mutation into a diverse panel of P450 scaffolds, we were able to quickly identify 
enantioselective catalysts for all possible diastereomers in the model reaction of styrene with ethyl 
diazoacetate. Some alanine variants exhibited selectivities that were markedly different from the 
wild-type enzyme, with a few possessing moderate to high diastereoselectivity and 
enantioselectivities up to 97 % for synthetically challenging cis-cyclopropane diastereomers.
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One approach to uncovering new modes of enzyme catalysis is to use man-made reagents 
that provide access to reactive intermediates not typically found in nature.[1] For example, 
intermolecular metal-catalyzed cyclopropanation is a well-characterized reaction that 
enables functionalization of olefins with a variety of synthetic carbene precursors. 
Cyclopropanes are valuable synthetic targets due to their presence in natural products and 
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pharmaceuticals, as well as their use as synthetic intermediates that undergo stereoselective 
ring-opening transformations.[2] A variety of transition metal complexes, including 
metalloporphyrins similar to the native prosthetic group hemin, have been applied for this 
transformation, but the design of competent catalysts that demonstrate high diastereo- and 
enantioselectivity has remained challenging.[3]
Recent work by Arnold and Fasan has shown that heme-containing proteins, including 
members of the cytochrome P450 family of enzymes (P450s) and myoglobin, promote the 
promiscuous cyclopropanation of styrenes in the presence of diazoacetates.[4] In contrast to 
free hemin, which produces a racemic mixture of predominantly trans-cyclopropanes with 
low total turnover number (TTN), several native heme proteins exhibit weak to moderate 
stereoinduction and modest catalytic efficiency.
Engineering efforts toward cyclopropanation catalysts derived from myoglobin and the 
bacterial P450BM3 have resulted in increased activity and have led to the facile isolation of 
highly trans-selective enzymes. For example, an engineered myoglobin with two mutations 
from the wild-type protein showed near-perfect selectivity in the cyclopropanation of 
styrene, with ethyl diazoacetate (EDA) producing the 1S,2S isomer with >99 % 
conversion.[4a] Mutations have also been shown to affect activity. Whereas wild-type 
P450BM3 is a weak cyclopropanation catalyst (<5 TTN), a single active-site mutation, 
T268A, improved the TTN ~65 fold and produced a variant that was highly selective for the 
1S,2S isomer (99:1 dr, 97 % ee; Figures 1 and 2, Table 1).[4b] Together, these studies 
demonstrate that the architecture of heme binding pockets can be leveraged to improve 
selectivity in intermolecular cyclopropanation reactions.
Despite these efforts, engineering biocatalysts that are selective for thermodynamically 
unfavorable cis-diastereomers remains a challenge. Cis-selective catalysts for the 
cyclopropanation of styrene with EDA have been identified by screening a library of 
P450BM3 variants possessing diverse active sites (P450BM3-CIS-T438S, Figure 1 and Table 
1);[4b,5] however, these catalysts contained a large number of mutations (>10), most of 
which were acquired over a decade of directed evolution. Identifying similar trajectories in 
other, non-cis-selective scaffolds would require considerable engineering and screening 
efforts. In addition, minor substitutions on styrene lead to attenuated or even reversed 
selectivity (vide infra).[4b,5] The difficulty in engineering cis-selective enzymes illustrates 
the challenge of using a single protein scaffold to alter both diastereo- and enantioselectivity.
We hypothesized that we could access stereoselective cyclopropanation catalysts by 
sampling a diverse library of natural P450 active sites and by introducing strategic mutations 
informed by previous P450BM3 engineering efforts. In P450BM3, a single mutation, T268A, 
significantly improves activity and selectivity, and the majority of highly active P450BM3 
variants contain this mutation (Figures 1 and 2, Table 1).[4b] Because this threonine is highly 
conserved, we reasoned that this mutation might affect cyclopropanation activity and 
selectivity in other scaffolds. Here, we show that a small library composed of thirteen 
diverse P450s and their corresponding alanine variants allows rapid identification of 
selective biocatalysts for all four diastereomers of the cyclopropanation reaction.
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Given the ubiquity of P450s in nature, numerous gene sequences are known that encode 
scaffolds that catalyze a range of oxidative and reductive transformations on a wide variety 
of substrates. The vast number of P450s that have been characterized or hypothesized based 
on genome mining makes the selection of viable sequences a non-trivial endeavor. To guide 
our search, we used the bioinformatics tool Deacon Active Site Profiler 2 (DASP2), which 
allowed us to maximize diversity by identifying scaffolds that share motifs necessary for 
function (e.g., the heme-ligating cysteine, Figure 2) among sequences that share little overall 
sequence identity (see the Supporting Information).[6] From the DASP2 search, we 
identified hundreds of unique P450 sequences as potential candidates for library design. The 
library was further narrowed down to enzymes that fit at least two of the following criteria: 
1) P450s derived from bacterial origin or previously produced in Escherichia coli (to 
facilitate heterologous expression), 2) P450s of known structure (to aid future protein 
engineering), and 3) sequences that shared <20 % sequence identity with P450BM3 (to 
maximize active site structural variation). Our final library comprised 16 P450s, including 
P450BM3, with diverse activities and substrate scopes (Tables S1 and S2 and Supporting 
Information text). The average sequence identity across the entire library was 24 %, and the 
maximum identity was 46 % (P450PikC and P450eryF; Figures S1 and S2). Each enzyme 
contained the conserved active site threonine, with the exceptions of P450eryF and 
CYP122A2, which contain an alanine and a serine, respectively, at this position (Figures S1 
and S3). The genes of the wild-type P450s and their corresponding alanine variants were 
synthesized by Gen9, Inc. Of the 31 wild-type and Thr→Ala constructs under investigation, 
25 proteins were successfully purified in sufficient quantity for screening (Figure S4 and 
Table S1).
All of the wild-type P450s screened were active catalysts for the cyclopropanation of styrene 
with EDA, though to varying extents (Table 1). The threonine to alanine mutation, which 
was previously found to strongly activate P450BM3 variants,[4b] induced similar 
enhancements in three scaffolds (P450nor, CYP107N1, and CYP164A2) that showed weak 
native activity (<50 TTN) but experienced three- to tenfold increases in TTN upon mutation 
(Table 1). For example, wild-type CYP164A2 displayed negligible activity (34 TTN), 
whereas CYP164A2-T260A produced cyclopropanes in 70 % yield (350 TTN). Even in the 
absence of the mutation, nine of the wild-type P450s showed considerable activity (>200 
TTN), thus indicating that the mutation is not absolutely required for high activity (Table 1). 
In some scaffolds, a small but significant decrease in activity was observed upon mutation, 
with P450cam-T252A and P450RhF-T274A showing 27 and 33 % decreases, respectively. 
Interestingly, wild-type P450eryF, which contains an alanine in place of the highly conserved 
threonine, was the most active wild-type P450 and one of the most active enzymes screened 
(349 TTN).
Most of the variants were trans-selective and showed hemin-like product profiles. A subset, 
however, possessed notable stereoselectivity (Table 1). P450PikC-T247A and P450BM3-
T268A showed impressive trans-diastereoselectivity (93:7 and 99:1 dr, respectively) and 
moderate to excellent enantioselectivity (32 and 97 % ee) for the 1R,2R and 1S,2S isomers, 
respectively. The selectivity of P450BM3-T268A was consistent with previous reports.[4b] In 
both variants, the threonine to alanine mutation improved enantioselectivity. Interestingly, 
five P450s in the library were cis-selective, including a few that were highly enantioselective 
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for the 1R,2S and 1S,2R isomers. Wild-type P450cam produced the 1S,2R enantiomer (88:12 
dr) with moderate enantioselectivity (43 %), which improved to 86 % ee (71:29 dr) for the 
T252A variant. P450eryF, which natively contains the active site alanine, and CYP142-
T234A showed strong preference for the 1S,2R isomer, catalyzing the reaction with ~90:10 
dr and ≥97 % ee. Substituting the conserved threonine with alanine had a drastic effect on 
P450BioI, transforming the trans-selective scaffold into a highly cis-selective catalyst with 
unprecedented enantioselectivity among biocatalysts for the 1R,2S isomer (95 % ee, 71:29 
dr). Notably, this simple, limited diversity library produced selective variants for all four 
possible ethyl-2-phenylcyclopropanecarboxylate diastereomers (Figure 1, Table 1).
To assess how selectivity translated to other substrates, we briefly explored the substrate 
scope of our most selective variants compared to previously engineered trans- and cis-
selective P450BM3 variants (P450BM3-T268A and P450BM3-CIS-T438S, respectively).[4b] We 
screened variants against styrenes with substituents at the α-vinyl position (1 b) and with 
electron donating or withdrawing substituents on the aromatic ring (1 c and 1 d, 
respectively). Tolerance to substitutions varied widely depending on the protein scaffold 
(Table 2). Trans-selective scaffolds P450BM3-T268A and P450PikC-T247A, identified by 
using styrene as a model substrate, retained moderate to high activity and trans-
diastereoselectivity toward all substrates tested. Conversely, the cis-selective enzymes 
demonstrated more variability. For example, P450BM3-CIS-T438S retained cis-selectivity 
against methoxy-substituted styrene 1 c but became a trans-selective enzyme when presented 
with electron withdrawing substituents and increased branching on the olefin. P450BioI-
T238A showed improved cis-selectivity in the presence of α-methyl styrene (1b); however, 
substitutions on the styrene ring led to diminished or reversed diastereoselectivity. CYP142-
T234A, however, remained highly cis-selective and displayed high enantioselectivity (>90 % 
ee) for all substrates tested. Despite the difficulties in predicting trends, moderate to high 
selectivity for encumbered cis diastereomers was observed for each model substrate, using 
only a small P450 library.
Interestingly, the most active and stereoselective variants presented in this study contained 
the mutation of the active site threonine to alanine, and the mutation tended to increase 
activity and/or selectivity in over half of the enzymes screened. This highly conserved 
residue is located in the kinked region of the i-helix (Figure S3) and has been proposed to 
facilitate proton delivery, activation of molecular oxygen, and the stabilization of other 
catalytic intermediates.[7] In cysteine-ligated P450BM3 variants, the T268A mutation is 
required for cyclopropanation activity. This observation initially led us to hypothesize that 
mutation to a smaller residue might relieve steric clash that prevents favorable binding of 
reactants. However, mutating the active site threonine to valine, a residue that is similar in 
size, also produced a highly active variant with similar selectivity to P450BM3-T268A 
(Figure S5). Alternatively, enzyme inactivation might result from direct carbenoid insertion 
into the protein scaffold (e.g., O–H insertion into the threonine side chain). However, no 
change in protein mass was observed after incubating the enzyme with styrene and ethyl 
diazoacetate. Although the mutation does not appear to cause significant changes to 
secondary and tertiary structure in P450BM3 (RMSD of 0.5 Å between the wild-type and 
T268A structures, 2IJ2 and 1YQO, respectively), backbone rearrangements in this region 
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have been observed in other P450 crystal structures.[8] The mutation might alter hydrogen 
bonding networks, active site water composition, or protein dynamics that affect enzymatic 
cyclopropanation in a manner that has yet to be elucidated.
In summary, we have shown that natural P450 diversity provides a rich and rapid means for 
identifying biocatalysts with moderate to high selectivity for most cyclopropane 
diastereomers, including cis diastereomers that are traditionally difficult to produce. In 
addition, mutations identified in previous engineering experiments can guide library design, 
increasing the likelihood of isolating robust and stereoselective catalysts. Although the 
effects of the conserved threonine to alanine mutation are not universal, it provides an 
important target for engineering P450-based cyclopropanation catalysts. Importantly, 
incorporation of this mutation enabled the discovery of cis-selective catalysts that would not 
have been discovered by screening only the wild-type enzymes. Although there remains 
room for improvement, this work shows that a diversity-based strategy for incorporating key 
mutations can help create small, focused libraries that provide rapid access to selective 
starting points for further engineering and laboratory evolution.
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Figure 1. 
Styrene cyclopropanation with ethyl diazoacetate catalyzed by P450 variants. Chiral GC 
traces are aligned to provide a visual representation of product distributions.
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Figure 2. 
Active site of substrate-free P450BM3 (PDB ID: 2IJ2). Conserved residues Thr268, Phe393, 
and Cys400 are shown in green, and the heme cofactor is shown in purple.
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